[改良的NHL-BFM-90方案治疗弥漫性大B细胞淋巴瘤患者]
[The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma].
作者信息
Magomedova A U, Kravchenko S K, Kremenetskaia A M, Zvonkov E E, Bariakh E A, Margolin O V, Kaplanskaia I B, Vorob'ev I A, Samoĭlova R S, Obukhova T N, Moiseeva T N, Zybunova E E, Gemdzhian E G, Vorob'ev A I
出版信息
Ter Arkh. 2006;78(10):44-7.
AIM
To investigate efficacy of the modified protocol NHL-BFM-90 in patients with diffuse large B-cell lymphosarcoma (DLBCLS).
MATERIAL AND METHODS
A total of 13 DLBCLS patients with stage II-IV of the disease with affection of lymph nodes at the disease onset (nodal lesion) and stage II with tumor size more than 10 cm (bulky disease) received first-line treatment according to the modified program NHL-BFM-90 from 2002 to 2005. The diagnosis was made by WHO criteria.
RESULTS
A complete remission was achieved in 76.9% patients. Resistance to therapy was observed in the patients with bone marrow affection. The 2.5-year overall survival was 74%, 2-year event-free survival was 75% (the events were recurrence and resistance). Follow-up continued from 5 to 47 months.
CONCLUSION
The efficacy of the modified protocol NHL-BFM-90 in DLBCLS patients with stage III-IV of the "nodal" disease and stage II of the "bulky" disease was high.
目的
研究改良的NHL-BFM-90方案治疗弥漫性大B细胞淋巴瘤（DLBCLS）患者的疗效。
材料与方法
2002年至2005年，共有13例疾病分期为II-IV期、疾病初发时伴有淋巴结受累（淋巴结病变）以及II期肿瘤大小超过10 cm（巨大肿块型病变）的DLBCLS患者按照改良的NHL-BFM-90方案接受一线治疗。诊断依据世界卫生组织标准。
结果
76.9%的患者实现完全缓解。骨髓受累患者出现治疗抵抗。2.5年总生存率为74%，2年无事件生存率为75%（事件为复发和抵抗）。随访持续5至47个月。
结论
改良的NHL-BFM-90方案对“淋巴结”疾病III-IV期和“巨大肿块型”疾病II期的DLBCLS患者疗效显著。
Zotero 插件